MedCity News December 15, 2025
Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment.
Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 development offering a different approach and the potential for use as an earlier treatment for the prevalent arthritic disorder.
While drugs for gout are available, they either offer limited efficacy or come with dangerous complication risks. The Arthrosi acquisition announced Monday puts Stockholm-based Sobi in position to address patients...
Today's Sponsors
Today's Sponsor